Current status of lupus nephritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Author-Supplied Keywords:
      Autoimmune disorder
      immunosuppressive therapy
      lupus nephritis
      systemic lupus erythematosus
      treatment
    • Abstract:
      Systemic lupus erythematosus (SLE) is a systemic disease of unknown aetiology with variable course and prognosis. Lupus nephritis (LN) is one of the important disease manifestations of SLE with considerable influence on patient outcomes. Immunosuppression therapy has made it possible to control the disease with improved life expectancy and quality of life. In the last few decades, various studies across the globe have clarified the role, dose and duration of immunosuppression currently in use and also provided evidence for new agents such as mycophenolate mofetil, calcineurin inhibitors and rituximab. However, there is still a need to develop new and specific therapy with less adverse effects. In this review, the current evidence of the treatment of LN and its evolution, and new classification criteria for SLE have been discussed. Also, rationale for low-dose intravenous cyclophosphamide as induction agent followed by azathioprine as maintenance agent has been provided with emphasis on individualized and holistic approach. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Indian Journal of Medical Research is the property of Indian Council of Medical Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Department of Nephrology, Indira Gandhi Medical College (IGMC), Shimla, India
    • ISSN:
      0971-5916
    • Accession Number:
      10.4103/ijmr.IJMR_163_16
    • Accession Number:
      123751806
  • Citations
    • ABNT:
      JARYAL, A.; VIKRANT, S. Current status of lupus nephritis. Indian Journal of Medical Research, [s. l.], v. 145, n. 2, p. 167–178, 2017. DOI 10.4103/ijmr.IJMR_163_16. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=aph&AN=123751806. Acesso em: 4 jul. 2020.
    • AMA:
      Jaryal A, Vikrant S. Current status of lupus nephritis. Indian Journal of Medical Research. 2017;145(2):167-178. doi:10.4103/ijmr.IJMR_163_16.
    • AMA11:
      Jaryal A, Vikrant S. Current status of lupus nephritis. Indian Journal of Medical Research. 2017;145(2):167-178. doi:10.4103/ijmr.IJMR_163_16
    • APA:
      Jaryal, A., & Vikrant, S. (2017). Current status of lupus nephritis. Indian Journal of Medical Research, 145(2), 167–178. https://doi.org/10.4103/ijmr.IJMR_163_16
    • Chicago/Turabian: Author-Date:
      Jaryal, Ajay, and Sanjay Vikrant. 2017. “Current Status of Lupus Nephritis.” Indian Journal of Medical Research 145 (2): 167–78. doi:10.4103/ijmr.IJMR_163_16.
    • Harvard:
      Jaryal, A. and Vikrant, S. (2017) ‘Current status of lupus nephritis’, Indian Journal of Medical Research, 145(2), pp. 167–178. doi: 10.4103/ijmr.IJMR_163_16.
    • Harvard: Australian:
      Jaryal, A & Vikrant, S 2017, ‘Current status of lupus nephritis’, Indian Journal of Medical Research, vol. 145, no. 2, pp. 167–178, viewed 4 July 2020, .
    • MLA:
      Jaryal, Ajay, and Sanjay Vikrant. “Current Status of Lupus Nephritis.” Indian Journal of Medical Research, vol. 145, no. 2, Feb. 2017, pp. 167–178. EBSCOhost, doi:10.4103/ijmr.IJMR_163_16.
    • Chicago/Turabian: Humanities:
      Jaryal, Ajay, and Sanjay Vikrant. “Current Status of Lupus Nephritis.” Indian Journal of Medical Research 145, no. 2 (February 2017): 167–78. doi:10.4103/ijmr.IJMR_163_16.
    • Vancouver/ICMJE:
      Jaryal A, Vikrant S. Current status of lupus nephritis. Indian Journal of Medical Research [Internet]. 2017 Feb [cited 2020 Jul 4];145(2):167–78. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=aph&AN=123751806